Treatment of Acute Lymphoblastic Leukemia in Lymphoblastic Lymphoma

Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia share the same biological entity and are separated by a single diagnostic threshold. Because of this close relationship, managing ALL arising in the context of LBL requires a carefully structured approach that addresses both the lymphoma diagnosis and potential acute complications at presentation.

Clinical scenario

Lymphoblastic lymphoma is a rare entity, representing 1% to 3% of all non-Hodgkin lymphomas. LBL and ALL are separated by an arbitrary cut-point of 25% bone marrow infiltration — below this threshold the diagnosis is LBL; above it, ALL. Despite this distinction, the two conditions share a common treatment framework.

Treatment approach

In a minority of cases, acute complications at diagnosis — including thoracic compression — may require immediate intervention with corticosteroids before systemic therapy can begin. The broader treatment strategy follows ALL-based regimens and incorporates CNS prophylaxis in line with ALL protocols. The full regimen, sequencing, and decision algorithm are available in the structured protocol.

Treatment goal

Complete remission is the primary endpoint of first-line therapy.

CR rate 70% – 90%

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood.2023023568

Lymphoblastic lymphoma (LBL) is a rare entity of 1% to 3% NHL.
LBL and ALL are separated by an arbitrary cut-point of 25% BM infiltration.
Rarely, tumor lysis syndrome and, in some cases, thoracic compression require immediate therapeutic intervention by corticosteroids.
Treatment should be based on ALL regimens.
CNS prophylaxis is administered as in ALL.
The CR rate in most studies is 70% to 90%, the EFS is 60% to 70% at 5 years, and the OS range is also between 60% and 70%.

View source ↗